Burd, Amy
Levine, Ross L. http://orcid.org/0000-0002-7884-1905
Ruppert, Amy S.
Mims, Alice S. http://orcid.org/0000-0002-8971-2199
Borate, Uma
Stein, Eytan M.
Patel, Prapti
Baer, Maria R.
Stock, Wendy
Deininger, Michael http://orcid.org/0000-0002-2987-1331
Blum, William
Schiller, Gary
Olin, Rebecca
Litzow, Mark
Foran, James
Lin, Tara L. http://orcid.org/0000-0002-0242-6449
Ball, Brian http://orcid.org/0000-0002-4561-3340
Boyiadzis, Michael http://orcid.org/0000-0001-6699-6355
Traer, Elie
Odenike, Olatoyosi
Arellano, Martha
Walker, Alison
Duong, Vu. H.
Kovacsovics, Tibor
Collins, Robert http://orcid.org/0000-0003-0313-2394
Shoben, Abigail B.
Heerema, Nyla A.
Foster, Matthew C.
Vergilio, Jo-Anne
Brennan, Tim
Vietz, Christine
Severson, Eric
Miller, Molly
Rosenberg, Leonard
Marcus, Sonja
Yocum, Ashley
Chen, Timothy
Stefanos, Mona
Druker, Brian http://orcid.org/0000-0001-8331-8206
Byrd, John C. http://orcid.org/0000-0001-9830-0711
Funding for this research was provided by:
Center for Strategic Scientific Initiatives, National Cancer Institute (R35 CA198183)
Article History
Received: 2 March 2020
Accepted: 28 August 2020
First Online: 26 October 2020
Competing interests
: A.B., S.M., L.R. and A.Y. are employees of LLS. LLS receives funding from AbbVie, Agios Pharmaceuticals, Alexion Pharmaceuticals, Amgen, Astellas Pharma, AstraZeneca, Boehringer Ingelheim International, Boston Biomedical, Bristol Myers Squibb, Celgene, Genentech, Gilead Sciences, ImmunoGen, Jazz Pharmaceuticals, Johnson & Johnson, Novartis, Pfizer, Pharmacyclics, RTI Health Solutions, Shire and Takeda. R.L.L. has served on the supervisory board of QIAGEN, the scientific advisory boards of Loxo Oncology (until 2019), Imago BioSciences, Mission Bio, Mana Therapeutics, Auron Therapeutics, C4 Therapeutics and Isoplexis (including equity interest). He has received research support from and consulted for Celgene and Roche, was a consultant for Incyte Corporation, Eli Lilly and Company, Janssen Pharmaceutica, Astellas Pharma, MorphoSys and Novartis, and has received research support from Prelude Therapeutics and honoraria from AstraZeneca, Roche, Eli Lilly and Company and Gilead Sciences. A.S.M. has served on the advisory boards of Jazz Pharmaceuticals, AbbVie/Genentech, Astellas Pharma, PTC Therapeutics, Novartis, Agios Pharmaceuticals and Syndax Pharmaceuticals. U.B. has been a consultant for Genetech, Daiichi Sankyo, Takeda, Pfizer, AbbVie/Genetech and Novartis. E.M.S. has served on the advisory boards of Astellas Pharma, AbbVie, Genentech, Daiichi Sankyo, Novartis, Amgen, Seattle Genetics, Syros Pharmaceuticals, Syndax Pharmaceuticals, Agios Pharmaceuticals and Celgene. He is an equity holder in Auron Therapeutics. P.P. has served on the advisory board of Agios Pharmaceuticals. W.S. has served on the advisory boards of Astellas Pharma, Agios Pharmaceuticals, Kite Pharma, Jazz Pharmaceuticals, Servier, MorphoSys and Amgen, and has received speaking honoraria from AbbVie and Pfizer. M.D. has served on the advisory boards of Blueprint Medicines, Takeda, Incyte Corporation and Sangamo Therapeutics. He has been a consultant for Blueprint Medicines, Fusion Pharmaceuticals, Medscape, Novartis, Sangamo Therapeutics and DisperSol Technologies and has received research funding from Blueprint Medicines, Takeda, Novartis, Incyte Corporation, Sun Pharma Advanced Research Company and Pfizer. He has served on the study management committees of Blueprint Medicines and Takeda. W.B. has received research funding from Forma Therapeutics, Xencor and Celyad Oncology and honoraria from AmerisourceBergen. G.S. has served on the advisory boards of Incyte Corporation, ElevateBio, AbbVie, Karyopharm Therapeutics, ONO Pharma UK, Novartis, Evidera, Agios Pharmaceuticals, AstraZeneca, NCI and FDA. He has received research funding from AbbVie, Agios Pharmaceuticals, Actinium Pharmaceuticals, Ambit Biosciences, Amgen, ARIAD Pharmaceuticals, Astellas Pharma, LLS, BioMed Valley Discoveries, Bristol Myers Squibb, Celator Pharmaceuticals, Celgene, Constellation Pharmaceuticals, Forma Therapeutics, Cyclacel Pharmaceuticals, Daiichi Sankyo, Deciphera Pharmaceuticals, California Institute for Regenerative Medicine, Gamida Cell, Gilead Sciences, Incyte Corporation, Janssen Pharmaceutica, Karyopharm Therapeutics, Kite Pharma, Mateon Therapeutics, MedImmune, Millenium, National Marrow Donor Program, NIH, Novartis, Onconova Therapeutics, Onyx Pharmaceuticals, Pfizer, Sangamo Therapeutics, Stemline Therapeutics, Tolero Pharmaceuticals, Trovagene (Cardiff Oncology), University of California, Davis, University of California, San Diego and the University of California Hematologic Malignancies Consortium. He has received stock from Amgen, Bristol Myers Squibb, Pfizer and Johnson & Johnson. He has served on the speakers’ bureaux of Agios Pharmaceuticals, Amgen, Astellas Pharma, Bristol Myers Squibb, Celgene, Sanofi Genzyme, Incyte Corporation, Janssen Pharmaceutica, Jazz Pharmaceuticals, Kite Pharma (Gilead Sciences), Pharmacyclics and Stemline Therapeutics. R.O. has been a consultant for and received honoraria from Jazz Pharmaceuticals, Genentech, Amgen and Revolution Medicines and has received research funding from Daiichi Sankyo, Astellas Pharma, Pfizer, Genentech, Takeda, Novartis, AstraZeneca, MedImmune (AstraZeneca), Spectrum Pharmaceuticals and Mirati Therapeutics. J.F. has been on the advisory boards of Novartis, Servier and Pfizer. He has been a consultant for Revolution Medicine and has received research funding from AbbVie, Boehringer Ingelheim, Actinium Pharmaceuticals, Aprea Therapeutics, Aptose Biosciences, H3 Biomedicine, Kura Oncology, Tolero Pharmaceuticals, Trillium Therapeutics, Xencor and Takeda/Millennium. E.T. has served on the advisory boards of AbbVie, Astellas Pharma, Genentech, Agios Pharmaceuticals and Daiichi Sankyo. He has received clinical trial support from Janssen Pharmaceutica and clinical trial funding and sponsored research from Incyte Corporation. He holds equity in Notable Labs. O.O. has served on the advisory boards of AbbVie, Celgene and Impact Biomedicines. She has received research funding from AbbVie, AstraZeneca, Astex, Agios Pharmaceuticals, Celgene, CTI BioPharma, Incyte Corporation, Janssen Pharmaceutica, Kartos Therapeutics, NS Pharma and OTS. M.A. has served on the advisory boards of Gilead Sciences and Syndax Pharmaceuticals. M.C.F. has been a consultant for Agios Pharmaceuticals, MacroGenics and Daiichi Sankyo and has received research funding from the LLS. J.-A.V. is an employee of Foundation Medicine, a wholly owned subsidiary of Roche Holdings and with equity interest in Roche Holdings. E.S. is an employee of Foundation Medicine with equity interest in Roche Holdings. B.D. has served on the scientific advisory boards of Aileron Therapeutics, Therapy Architects (ALLCRON), Cepheid, Vivid Biosciences, Celgene, RUNX1 Research Program, EnLiven Therapeutics, Gilead Sciences (inactive), Monojul (inactive). He has served on the scientific advisory boards of and received stock from Aptose Biosciences, Blueprint Medicines, Iterion Therapeutics, Third Coast Therapeutics, GRAIL (scientific advisory board, inactive). He is the scientific founder of MolecularMD (inactive, acquired by ICON). He has served on the board of directors of and received stock from Amgen. He has served on the board of directors of Burroughs Wellcome Fund and CureOne, the joint steering committee of Beat AML LLC. He is the founder of VBL Therapeutics, has received clinical trial funding from Novartis, Bristol Myers Squibb and Pfizer and royalties from patent no. 6958335 (Novartis exclusive license), OHSU and the Dana-Farber Cancer Institute (one Merck exclusive license). J.C.B. has received research support from Janssen Pharmaceutica, Genentech, Acerta Pharma and Pharmacyclics and has served on the advisory board of Syndax Pharmaceuticals. He has received funding from the NCI (grant no. R35 CA198183) and in part through an NIH/NCI Cancer Center Support grant no. P30 CA008748. M.R.B., R.C., T.K., B.B., M.B., T.B., V.H.D., N.A.H., M.L., M.M., A.S.R., A.B.S., M.S., T.L.L., C.V. and A.W. declare no conflicting interests.